BridgeBio Oncology Therapeutics, Inc.
↗South San Francisco, USA
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation small molecule therapeutics for cancers driven by the RAS and PI3Kα pathways. Originally established as a subsidiary of BridgeBio Pharma, the company focuses on 'undruggable' targets by utilizing novel mechanisms such as ON/OFF state inhibition and RAS:PI3Kα interaction breakers.
BBOT became a standalone public entity in 2025 following a business combination with Helix Acquisition Corp. II. The company's strategy involves targeting the most prevalent oncogenes in human tumors with high-potency, well-tolerated inhibitors that can be used as monotherapies or in synergistic combinations to overcome adaptive resistance in solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M (Clinical Stage)
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$396M
Investors:Omega Funds, Cormorant Asset Management, BridgeBio Pharma, Helix Acquisition Corp. II, Deerfield Management, EcoR1 Capital
STOCK
Exchange:NASDAQ
Ticker:BBOT
Market Cap:$802M
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule
Active Trials:3
Trial Phases:Phase 1: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:BridgeBio Pharma (Significant Shareholder)
Key Partnerships:BridgeBio Pharma (R&D and shared services), Cormorant Asset Management (Strategic partner via SPAC)
COMPETITION
Position:Emerging
Competitors:Revolution Medicines, Amgen, Bristol Myers Squibb, Eli Lilly, Mirati Therapeutics
LEADERSHIP
Key Executives:
Eli Wallace, PhD - CEO
Uneek Mehra - CFO
Pedro J. Beltran, PhD - Chief Scientific Officer
Scientific Founders:Frank McCormick, PhD
Board Members:Frank McCormick (Chairman), Bihua Chen, Neil Kumar, Michelle Doig
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BridgeBio Oncology Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BridgeBio Oncology Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.